Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Long-Term Debt Repayments (2024 - 2025)

Rani Therapeutics Holdings (RANI) has 2 years of Long-Term Debt Repayments data on record, last reported at $3.8 million in Q3 2025.

  • For Q3 2025, Long-Term Debt Repayments rose 200.0% year-over-year to $3.8 million; the TTM value through Sep 2025 reached $15.0 million, up 1100.0%, while the annual FY2024 figure was $5.0 million, N/A changed from the prior year.
  • Long-Term Debt Repayments reached $3.8 million in Q3 2025 per RANI's latest filing, roughly flat from $3.8 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $3.8 million in Q4 2024 and bottomed at $1.2 million in Q3 2024.